Definitive Contract HHSN272201700066C
Award Date
7/31/17
Potential Completion Date
7/31/18
Potential Value
$223K
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Adjuvance Technologies Inc.
Ultimate Awardee
Not listed
NAICS Category
541711 - Research and Development in Biotechnology
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
New York, NY 10010, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
5
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) awarded a firm fixed price purchase order contract to Advanced Bioadjuvants, LLC, a self-certified small disadvantaged business. The contract is for license fees related to the Adjuplex trademark, patents, and trade secret manufacturing process, which NIAID will use to combine with human vaccines for clinical trials. The contract has a 12-month...
This is a cost-type definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Virovax LLC, a minority-owned limited liability company, for an Adjuvant Development Program. The contract has a ceiling value of $9,273,316.19 and a period of performance through September 29, 2025. The contract was awarded on September 30, 2018 and does not utilize a set-aside designation. As NIAID is the funding agency, this award is likely supporting the...
This federal contract award is for the development of UM-1098, a novel synthetic TH17 inducing adjuvant and delivery system. The prime contractor is the University of Montana, and major subcontractors include West Virginia University Research Corporation, Inimmune Corp, and the University of Chicago. The funding agency is the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the National Institutes of Health (NIH) within the U.S. Department of Health and Human...
This is a $224,981.00 firm-fixed-price definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services, to Epitogenesis Inc., a minority-owned, economically disadvantaged women-owned small business. The contract is for the development of "A NUTRITIVE VACCINE ADJUVANT AGAINST INFLUENZA" and has a period of performance ending on September 14, 2015. The contract was set aside for small businesses.
This is a $4,259,653 cost-no-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH) under the Department of Health and Human Services (HHS), to Inimmune Corp, a biotechnology company based in Missoula, Montana. The contract is for the development of a synthetic AS01-like adjuvant system for influenza vaccines. Inimmune Corp has received several previous prime contract awards and sub-contract...
This federal contract award is for the development of an adjuvant for a thermostable respiratory influenza vaccine. The contract, valued at $599,749.00, was awarded to Universal Stabilization Technologies, Inc. by the Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases under the Small Business Innovation Research (SBIR) Program Phase I. The contract is a Definitive Contract with a Firm Fixed Price pricing type, and the...
The Department of Health and Human Services' National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $375,000 firm fixed price purchase order to Advanced Bioadjuvants, LLC of Omaha, Nebraska. The three-year contract, running from September 2021 through September 2024, provides a non-exclusive license to Advanced Bioadjuvants' Adjuplex adjuvant technology. This will allow the National Institute of Allergy and Infectious Diseases to manufacture cGMP grade...
This federal contract award for $18,472,563.99 was issued by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to the University of Montana. The contract's objective is to identify novel adjuvant candidates that can be used to augment the efficacy of human vaccines. Research under this definitive, cost-no-fee contract will contribute to the pipeline of new adjuvant leads that either exploit the innate immune system or act directly...
This federal contract award, valued at $5,822,726.00, was issued by the National Institute of Allergy and Infectious Diseases (NIAID) to Duke University. The contract is for the "ADJUVANT COMPARISON AND CHARACTERIZATION" project, which aims to compare multiple vaccine adjuvants using various vaccine and antigen platforms through comprehensive immune assessments. The contract does not have a set-aside designation. This contract is part of a broader NIAID program that seeks to...
This is a $3,000,000 firm fixed-price Small Business Innovation Research (SBIR) Phase II contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Adjuvax LLC, a small disadvantaged and minority-owned business located in Birmingham, Alabama. The contract supports research and development under SBIR Topic 130, which focuses on discovering and down-selecting vaccine adjuvants for infectious and...